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PLANPhospholipase A2 associated neurodegeneration (PLAN) is a major phenotype of autosomal recessive Neurode-
generation with Brain Iron Accumulation (NBIA). We describe the clinical phenotypes, neuroimaging features
and PLA2G6 mutations in 5 children, of whom 4 presented with infantile neuroaxonal dystrophy (INAD). One
other patient was diagnosed with the onset of PLAN in childhood, and our report highlights the diagnostic chal-
lenges associatedwith this atypical PLAN subtype. In this series, the neuroradiological relevance of classical PLAN
features as well as apparent claval hypertrophy’ is explored. Novel PLA2G6mutations were identiﬁed in all pa-
tients. PLAN should be considered not only in patients presenting with a classic INAD phenotype but also in
older patients presenting later in childhood with non-speciﬁc progressive neurological features including social
communication difﬁculties, gait disturbance, dyspraxia, neuropsychiatric symptoms and extrapyramidal motor
features.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
‘Neurodegeneration with Brain Iron Accumulation’ (NBIA) encom-
passes a group of disorders characterised by progressive motor symp-
toms, neurological regression and radiologically discernible brain iron
accumulation [1–4]. Themajor childhood NBIA syndromes include pan-
tothenate kinase associated neurodegeneration (PKAN; MIM#234200)
[5], fatty acid hydroxylase associated neurodegeneration (FAHN;
MIM#612319) [6], mitochondrial membrane protein associated neuro-
degeneration (MPAN; MIM#614298) [7], beta-propeller proteiniatric Neurology andWellcome
, Institute of Child Health, 30
.
. This is an open access article underassociated neurodegeneration (BPAN;MIM#300894) [8], and phospho-
lipase A2 associated neurodegeneration (PLAN; MIM#256600). PLAN is
an autosomal recessive disorder caused by mutations in the ubiqui-
tously expressed PLA2G6 gene (MIM*603604) [9]. PLA2G6 encodes the
85 kDa protein, iPLA2-VI which has key functions in maintaining cell
membrane homeostasis, through phospholipid remodelling, regulation
of apoptosis and catalysing the hydrolysis of glycerophospholipids [2,4,
6,10–13]. Features of the human disease are recapitulated in the PLA2G6
knockout mouse [14] with axonal spheroid formation secondary to
deranged cell membrane homeostasis leading to the accumulation of
membrane phospholipids and mitochondrial degeneration. PLA2G6-
associated disease is a continuum of three distinct, yet overlapping
phenotypes [6,10]: classic infantile neuroaxonal dystrophy (INAD)
(MIM#256600), atypical neuroaxonal dystrophy (NAD) of childhood-
onset (MIM#610217) and PLA2G6-related dystonia-parkinsonismthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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pathologically characterised by the presence of axonal spheroids and
progressive brain iron deposition and clinically by progressive motor
dysfunction and cognitive decline. We report 5 new cases of PLAN
and describe both infantile and atypical childhood-onset phenotypes
with novel radiological features and previously unreported PLA2G6
mutations.
2. Methods
Patients with clinical and radiological features suggestive of PLAN
were identiﬁed from tertiary neurology services in the UK and Ireland.
Recruiting paediatric neurology centres included Great Ormond Street
Hospital, Leeds General Inﬁrmary, Alder Hey Children's Hospital and
the Children's University Hospital Dublin. The patient medical notes
were reviewed to ascertain relevant clinical history and results of inves-
tigations. Where available, video footage of the affected children was
also examined. All availableMRneuroimagingwas reviewed by a paedi-
atric neuroradiologist. For most patients, PLA2G6 screening was under-
taken in the diagnostic setting by the West Midlands Regional Genetic
Service, Birmingham, UK. Direct Sanger sequencing of the coding re-
gions and ﬂanking intronic regions was undertaken for all patients
[15]. Additional multiplex ligation probe ampliﬁcation (MLPA) analysis
for Patient 4 was also performed using previously described primers
and techniques [15].
3. Clinical cases
3.1. Case 1
A female infant, born to non-consanguineous Caucasian parents,
presented at 15 months of age with global developmental regression.
Early development had been age appropriate until 12 months of age.
Her development thereafter plateaued, with regression from 14 months.
She lost all previously acquired vocabulary, ﬁnemotor skills and the abil-
ity to sit. Choking during feeds and excess drooling suggested the onset
of bulbar dysfunction. She was non-dysmorphic. Axial tone was reduced
with peripheral hypertonicity and hyperreﬂexia. Plantar responses were
down-going. Ophthalmological examinationwas normal. A rapid clinical
decline ensued. Deteriorating bulbar function necessitated gastrostomy
tube feeding at 20 months. At 26 months of age spontaneousmovement
was minimal with arreﬂexia (Table 1).
Electroencephalogram (EEG) showed diffuse slowing of background
activity with infrequent and brief paroxysms of bi-posterior sharp theta
and spike-slowwave activity, without clinical correlation (Table 2). Elec-
tromyogram (EMG) demonstrated changes consistent with chronic de-
nervation. Initial MRI brain scan (without T2* sequences) at 27 months
of age showed a hypoplastic cerebellum, small pons and vertically orien-
tated smooth splenium of the corpus callosum. There was evidence of
visual pathway atrophy and a small optic chiasm, with white matter
signal intensity, which may represent delayed myelination. There was
no evidence of brain iron deposition. Subsequent imaging at 39 months
with T2* sequences demonstrated iron deposition in the globus pallidus,
indicated by hypointensity on T2* sequences. The cerebellar hypoplasia
was non-progressive, with apparent claval prominence (Table 2, Fig. 1a
and b).
3.2. Case 2
A male infant, the ﬁrst child born to consanguineous ﬁrst cousin
Caucasian parents, presented at 12 months of age with developmental
arrest. Preceding history was unremarkable and acquisition of develop-
mental milestones in the ﬁrst year was age appropriate. He failed to ac-
quire skills thereafter and regressed from 15 months of age. He was
non-dysmorphic with axial hypotonia and hypertonicity of all 4 limbs.
Rapid neurocognitive decline ensued and by 15 months of age.Nystagmus and strabismus were evident with evolving four limb spas-
ticity and distal limb arreﬂexia. Ophthalmological examination at
18 months conﬁrmed optic atrophy. Bulbar dysfunction was suggested
by signiﬁcant drooling and gastrostomy feeding commenced at
24 months (Table 1).
EEG at 30 months of age shows high amplitude fast activity (Table 2,
Fig. 2). Neurophysiologywas consistentwith a sensorimotor axonal neu-
ropathy. MRI brain scan at 29 months (Table 2, Fig. 1c and d) showed
advanced cerebellar and pontine atrophy. A smooth, thin vertically ori-
entated splenium of the corpus callosum was present. Myelination was
delayed and the optic tracts underdeveloped with a small optic chiasm.
High signal in the cerebellar grey matter was consistent with gliosis.
Again, there was apparent claval prominence, without evidence of
brain iron deposition.
3.3. Case 3
Case 3 presented at 18 months of age with motor regression. She is
the only child of consanguineous Pakistani parents. Shewas born follow-
ing an uncomplicated pregnancy and attained early developmentalmile-
stones age appropriately. Following a febrile illness at 7 months of age,
her rate of acquisition of developmental milestones slowed. Regression
from18 months of agemanifested as progressiveweakness, loss of inde-
pendent ambulation and ‘unsteadiness’. By 24 months, she had lost ex-
pressive language and at 5.5 years she can no longer sit independently,
has no purposeful hand movement and requires a modiﬁed pureed
diet due to bulbar dysfunction. A gastrostomy is planned due to frequent
choking episodes. Paroxysmal events emerged at 2.5 years, involving
tonic posturing and stiffening without electrographic correlate. On ex-
amination, she has bilateral horizontal nystagmus and optic atrophy
but no strabismus. She is hypotonic axially with peripheral hypertonici-
ty, and contractures are evident at the knees and ankles with arreﬂexia.
Her vision has deteriorated over time and now, aged 5.5 years she has
no functional vision. Secretions and excessive drooling are managed
with transdermal hyoscine patches. Omeprazole, gavison and erythro-
mycin are used in the management of her gastro-oesophageal reﬂux.
Minimal beneﬁt is observed from the use of baclofen for tone manage-
ment. Lower limb plantar ﬂexion contractures aremanagedwith orthot-
ics, and she has been referred for bilateral tendon releases.
Initial EEG (2.5 years) demonstrates diffuse beta fast activity and
bilateral independent spike discharges, with anterior predominance.
MRI brain scan at 4.5 years (Fig. 1e and f) shows cerebellar hypoplasia
and T2 cerebellar high signal consistent with gliosis, underdevelopment
of the optic tracts with a small optic chiasm. There is a generalised lack
of cerebral white matter bulk and apparent claval prominence.
3.4. Case 4
Case 4 is male, the ﬁrst child born to his non-consanguineous, white
Caucasian parents. Antenatal, birth and family history is unremarkable.
He presented with global developmental regression from 22 months,
and preceding developmental milestones were attained age appropriate-
ly. Prior to presentation he used some single words appropriately, cruised
around furniture and had a functional bimanual pincer grip. A convergent
strabismus was apparent from 14 months which was managed with
patching, though over the subsequent months optic atrophy and visual
deterioration ensued. Regression at 22 months manifested as frequent
falls, loss of the ability to stand independently, reduced crawling and
loss of a pincer grip. He was no longer able to hold or drink from a two
handled beaker. Prolonged feeding times and an increased frequency of
choking were suggestive of evolving bulbar dysfunction. He currently ex-
periences paroxysmal events, with a history and semiology indicative of
breath holding spells. Recently nocturnal unprovoked apnoeic episodes
have emerged and overnight polysomnography implies a centrally medi-
ated mechanism. Examination at 24 months of age, demonstrated axial
hypotonia, profuse drooling and an open mouthed posture, suggestive
Table 1
Clinical features.
Case 1 2 3 4 5
Current age 6 yrs 8 yrs 7 yrs 30mo 17 yrs
Age at onset 8 months (developmental arrest) 12 months (developmental arrest) 18 months (developmental arrest) 22 months (developmental regression) 36 months (ataxia)
Axial hypotonia Yes Yes Yes Yes No
Spasticity 4 limb 4 limb 4 limb No Yes—lower limbs
Dystonia No No Yes—jaw No Yes—4 limb 11 years
Reﬂexes Brisk initially Arreﬂexia- 25 months Brisk initially Absent ankle jerks
30 months
Arreﬂexic Brisk Brisk—upper limbs
Arreﬂexic lower limbs
Plantar responses Extensor Extensor Equivocal Extensor Right downgoing Left equivocal
Optic atrophy No Yes Yes Yes No
Strabismus No Yes No Yes No
Nystagmus No Yes Yes No No
Hypometric saccades
Cerebellar signs Yes Yes Yes Yes Yes
Seizures No No Paroxysmal events, not conﬁrmed as seizures No No
Disease progression
Regression:Motor Sitting unsupported at 8 months.
Skills lost: 14 months.
Sitting unsupported at 8 months.
Standing: 12 months.
Skills lost: 15 months.
Sitting at 6 months, walked at 12 months.
Loss of walking at 18 months.
Unable to sit at 30 months.
Loss of head control: 5 years.
Walking with minimal support at 15 months.
Loss of supported walking: 22 months.
Deterioriation in sitting posture: 24 months.
Walking at 12 months. Ataxia: 3 years.
Acquisition of rollator: 14 years.
Regression:
Speech
Loss of vocabulary: 18 months. Loss of vocabulary: 15 months. Loss of vocabulary: 20 months. Loss of vocabulary: 22 months. Intermittent dysarthria: 14 years.
Ambulation Never achieved Never achieved Lost at 18 months Lost at 24 months Acquired rollator: 14 years
Bulbar dysfunction:
Age at onset
14 months: Feeding difﬁculties and drooling.
20 months: Gastrostomy
18 months: Drooling.
24 months: Gastrostomy.
5 years: Drooling, choking, and modiﬁed diet.
7 years: Gastrostomy.
23 months: Drooling, choking on feeds, and
prolonged feeding time.
16 years: Choking, prolonged feeding time.
Memory impairment:
Age at onset
14 years: Short term memory difﬁculties.
Table 2
Investigation ﬁndings.
Case MRIa
Cerebellar
atrophy
MRI T2
Cerebellar high signal
consistent with gliosis
MRI
Hypoplastic optic
chiasm and tracts
MRI
Iron depositon
MRI
Abnormal splenium of
corpus callosum
MRI
Claval
hypertrophy
VERsa EEGa EMGa NCSa Biopsy
Typical ﬁndings
in INAD
Almost
universal
Common Common Late sign—40–
50% cases
Vertically
orientated
Undetermined ↓ or absent High amplitude
fast activity
Denervation Distal axonal sensorimotor
neuropathy
Nerve—
axonal swelling and
spheroid bodies
1 Yes
Progressive
No Yes No Yes Yes Nil Abnormalb Denervation Axonal sensorimotor
neuropathy
Nil
2 Yes No Yes Yes—globus
pallidus
Yes Yes Nil Fast β2 activity Denervation Axonal sensorimotor
Neuropathy
Nil
3 Yes No Yes No Yes Yes Nil Fast β2 activity Nil Nil Nil
4 Yes
Progressive
Yes Yes No Yes Yes ↓ High amplitude
fast activity
Denervation Normal Skin
Normal
Typical ﬁndings
in atypical NAD
Yes Yes No Universal Thin, vertically
orientated
and smooth
Undetermined Normal Normal
Initially
Normal Normal Nerve—
axonal swelling and
spheroid bodies
5 Yes
Progressive
No No Yes Basal Ganglia Yes Yes Nil Nil Denervation Distal axonal sensorimotor
neuropathy
Muscle biopsy—
neurogenic changes
Respiratory chain enzymes—
↓Cytochrome oxidase—
0.007 (0.014–0.034)
a MRI: magnetic resonance imaging. VERs: visual evoked responses. EEG: electroencephalogram. EMG: electromyogram. NCS: nerve conduction studies.
bBackground slowing with paroxysms of bi-posterior sharp theta and spike-slow wave activity, in wakefulness. 185
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Fig. 1. a. Midline sagittal T1 brain MRI of Case 1 at 27 months. b. Axial T2 weighted brain MRI of Case 1 aged 39 months, demonstrating iron deposition in the globus pallidus, which is
absent on earlier imaging (a). c. Midline sagittal T1 brain MRI of Case 2 aged 33 months, demonstrating classical features of typical PLAN (symbol key and Table 3) and apparent claval
hypertrophy. d. Axial T2* brain MRI of Case 2 aged 33 months, at the level of the globus pallidus; note the absence of iron deposition. e. Midline sagittal T1 brain MRI of Case 3 aged
4 years and 6 months, demonstrating classical features of typical PLAN and apparent claval hypertrophy. f. Axial FLAIR brain MRI of Case 3 aged 4 years and 6 months at level of cerebel-
lum, showing high signal of the cerebellar cortex, indicative of gliosis. There is no iron deposition. g. Midline sagittal T1 brain MRI of Case 4 aged 22 months, demonstrating cerebellar
atrophy, apparent claval hypertrophy and thin smooth splenium of the corpus callosum. h. Axial T2 weighted brain MRI of Case 4 aged 22 months, at the level of the globus pallidus.
There is no iron deposition. i. Midline sagittal T1 brain MRI of Case 5 aged 11 years, demonstrating cerebellar atrophy and apparent claval hypertrophy. j. Axial T2 brain MRI of Case 5
aged 16 years demonstrating iron deposition in the globus pallidus. k. Axial T2 brain MRI of Case 5 aged 16 years demonstrating iron deposition in the substantia nigra. l. Midline sagittal
T1 brain MRI of a 10 year old female with hemiplegic migraine and pathogenic CACNA1Amutation, demonstrating cerebellar atrophy and apparent claval hypertrophy.
Symbol key for Fig. 1
Thin vertically orientated smooth splenium of the corpus callosum
Cerebellar atrophy with high signal consistent with gliosis
Apparent claval hypertrophy
Shallow optic chiasm
Iron deposition in the globus pallidus
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movements without nystagmus. Power was at least antigravity and there
was no increase in dynamic tone or dystonia. Reﬂexes were brisk and
plantar responses were upgoing. He had no overt cerebellar features. He
remains alive at 30 months of age.
EEG at 24 months demonstrated excess fast activity. Changes consis-
tent with motor neuronopathy peripherally and of genioglossus were
detected on electromyogram (EMG). Whilst the electroretinogram
(ERG) was normal, visual evoked responses (VERs) were reduced.
A respiratory sleep study, undertaken in view of unprovoked apnoea
at night demonstrated central apnoeas at 26 months of age, and subse-
quently, he remains under the care of the respiratory physicians. A
videoﬂuorscopy is planned.
3.5. Case 5
This female child was born to non-consanguineous Caucasian
parents in good condition at 41 week gestation by ventouse extraction.Apart from some minor bleeding, the pregnancy was uneventful.
Early development was reassuring, with acquisition of gross motor,
ﬁne motor and speech and language skills age appropriately. Concerns
were ﬁrst expressed at 3 years, when she developed an unsteady,
broad based gait and she experienced some difﬁculty in settling in
the nursery school environment. Her gait remained ataxic, but stable
without further regression of skills and she commencedmainstreamed-
ucation. She then presented at 10 years of age with a 12 month history
of further gait deterioration, with poor balance, bilateral pes cavus de-
formity and left talipes equinovarus. Examination at 11 years demon-
strated brisk upper limb reﬂexes and absent lower limb reﬂexes with
equivocal plantar responses. A mild scoliosis was noted, which is man-
aged conservatively. Opthalmological assessment at 11 years conﬁrmed
hypometric eye saccades without nystagmus or strabismus. Features
evolved over time, with deterioration in independent mobility second-
ary to increasing ataxia and evolution of dystonic limb movements. At
16 years she acquired a rollator to facilitate independence. Her speech
is preserved, though intermittent dysarthria is reported. At present
Fig. 2. Electroencephalogram, Case 2 EEG of Case 2, aged 29 months in wakefulness, demonstrating fast beta2 activity (indicated by the red oval shape).
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prolonged and occasional swallowing difﬁculty is reported.
A clinical psychology assessment at 14 years demonstrated verbal
and non-verbal IQswithin the low-average range and conﬁrmed paren-
tal concerns regarding poorworkingmemory andword ﬁnding difﬁcul-
ties. She is described as ‘short-tempered’, ‘rigid’, ‘obsessional’ and
‘routine-orientated’. To date, treatment has been symptomatic. Achilles
tendon lengthening was undertaken at 11 years, without sustained
beneﬁt. Her mild scoliosis is monitored annually and at present she
does not require bracing or surgery. To date there have been no trials
of antispasmodic/dystonic agents.
EMG and NCS showed changes consistent with chronic denervation.
In light of these ﬁndings, a muscle biopsy was undertaken. Muscle
histopathology (Table 2) showed neurogenic changes and cytochrome
oxidase activity (COX, complex IV) was reduced at 0.007 (reference
0.014–0.034) on respiratory chain enzyme (RCE) analysis.
InitialMRI brain scan undertaken at 11 years of age showed cerebellar
hypoplasia and evidence of early iron deposition. Subsequent imaging at
16 years showedprogressive cerebellar atrophy andbrain irondeposition
in the substantia nigra and globus pallidus. (Table 2, Fig. 1k and l).
4. Molecular genetic investigations
All patients had either homozygous or compound heterozygous
mutations in the PLA2G6 gene (Table 3). Novel mutations were identi-
ﬁed in all patients including deletions, duplications, missense and non-
sense mutations.
5. Discussion
We report the clinical ﬁndings and neuroimaging features of 5
children (4 with phenotypes consistent with classic INAD and 1 with
atypical NAD) in whom novel PLA2G6 mutations were identiﬁed.Table 3
Mutational analysis.
Case Ethnicity Consanguinity Homozygous/heterozygous M
1 White Caucasian No Compound heterozygote D
M
2 White Caucasian Yes Homozygous M
3 Pakistani Yes Homozygous M
4 White Caucasian No Compound heterozygote D
5 White Caucasian No Compound heterozygote N
MPLA2G6mutations account overall for approximately 20% of childhood
onset NBIA [6]. Whilst the exact prevalence is unknown, it is estimated
at 1:1,000,000 [6]. Infantile-onset INAD is themost common, with a rel-
atively homogenous phenotype [1,6]. This is clearly illustrated in our
case series, all typical INAD patients presented prior to their third birth-
day, with neurodevelopmental regression, progressive 4 limb spasticity,
bulbar dysfunction and denervation on nerve conduction studies. In
keeping with published data, strabismus, optic atrophy, and fast
rhythms on EEG are commonly, but not universally reported [3]. Even
within this relatively homogenous group, a degree of phenotypic vari-
ability is often reported, as evident in Patients 1 and 2 who appeared
to have an arguably more aggressive disease course thanmost reported
patients with typical PLAN.
In contrast to INAD, the onset of atypical NAD is usually outside the
infantile period in early childhood (1.5–4.4 years) [4]. Atypical NAD is
less common than INAD, and the phenotype is more heterogeneous
rendering the diagnosis challenging. Autistic features with disordered
social communication and interaction may predominate initially, with
gait disturbance, tetraparesis, extrapyramidal features and cerebellar
signs evolving over decades [1,4]. In atypical NAD difﬁcult neuropsychi-
atric featuresmay evolve [1,4], a feature also observed in the third NBIA,
PLA2G6 phenotype-PARK14-linked parkinsonism [10,16,17]. In patients
with PARK14 early onset dystonia-parkinsonism (b30 years), PLA2G6
mutationsmay be identiﬁed in up to 6.9%. Typical presentation is in ad-
olescence, with the onset of parkinsonism [6,10,16]. Cognitive decline
and neuropsychiatric features thereafter predominate. In contrast with
infantile and childhood atypical NAD, speciﬁc neuroradiological chang-
es are minimal and in many cases only generalised cerebral atrophy is
demonstrated; frontotemporal atrophy with hypoperfusion on SPECT
may occur. Brain iron accumulation occurs late and is relatively rare
[6,10,16].
This report highlights the degree of phenotypic overlapwith atypical
NAD and the neuropsychiatric features of adult NBIA phenotypes.utation type DNA variant Protein change
uplication/Frameshift
issense
c.1524dupC
c.1798CNT
p.Lys509Glnfs*5
p.Arg600Trp
issense c.1756GNA p.Gly586Arg
issense c.2375ANC p.His792Pro
eletion/Frameshift Duplication c.1674delG
Duplication of exons 4–7
p.Leu560Trpfs*5
unknown
onsense
issense
c.2370TNG
c.691GNC
p.Tyr790*
P.Gly231Arg
188 M.A. Illingworth et al. / Molecular Genetics and Metabolism 112 (2014) 183–189Patient 5 who is described as ‘short-tempered’, ‘rigid’, ‘obsessional’ and
‘routine-orientated’ presented with a gradual onset of gait disturbance
and speech regression. Her clinical deterioration was insidious and
manifested as a slowly evolving movement disorder. At 16 years of
age she is ambulant, intermittently dysarthric and remains in main-
stream education.
Our case series highlights the classical neuroimaging features of
PLAN. Cerebellar hypoplasia and T2-weighted high signal in the cerebel-
lum (suggesting cerebellar gliosis), hypoplastic optic tracts/chiasm and
an elongated, vertically orientated splenium were seen in all typical
INAD cases reported here. Consistent with published data, iron deposi-
tion was not detected on initial neuroimaging in any of the infantile
cases (neuroimaging undertaken performed at 22–29 months) but
became evident in Case 1 on repeat imaging following a 12 month
interval. ‘Apparent claval hypertrophy’ with pontine atrophy has
been proposed as an early radiological marker of typical PLAN with
the presence of prominent spheroid bodies in the claval nuclei on histo-
pathology [18]. In this reported series, apparent claval hypertrophywas
evident in all typical and atypical cases of PLAN. However, we have
observed this radiological feature in other disorders associated with
cerebellar atrophy (Fig. 1l, Supplementary Fig. 1). Hence, we postulate
that the claval hypertrophy is not speciﬁc for PLAN and ismerely anoth-
er radiological feature aiding diagnosis but not pathognomonic for
PLAN, a likely epiphenomenon, reﬂecting adjacent pontocerebellar
atrophy as opposed to true hypertrophy of medullary structures.
The novel PLA2G6mutations reported in this series contribute to the
expanding spectrum of variants associated with PLAN. Whilst the
c.1634ANC, p.Lys545Thr homozygous mutation is common in some
Pakistani families [3], mutation heterogeneity is common with no evi-
dence of mutation hotspots. Current genetic sequencing methods
(Sanger sequencing and MLPA) detect a predicted 85%–90% of patho-
genic mutations. The remainder may represent intronic mutations and
promoter variants, unidentiﬁable by current diagnostic sequencing
methods [4,17]. Genotype–phenotype correlation in PLAN is not strik-
ingly obvious. Nevertheless, it has been postulated that those with
two null mutations tend to manifest the severe INAD phenotype whilst
compound heterozygotes for missense variants present later, with
atypical NAD [2]. We however report the unusual ﬁnding of a patient
with atypical NAD (Case 5) and the mildest phenotype of all our cases,
who is compound heterozygous for a novel missense mutation
and null mutation. In addition to allelic heterogeneity, it is likely that
other, currently undetermined genetic, epigenetic and environmental
factors contribute to phenotypic presentation.
PLA2G6 encodes the 85 kDa calcium-independent group VIA phos-
pholipase A2 enzyme, iPLA2β. Proposed pathogenic mechanisms relate
to its role in maintaining cell membrane homeostasis [24]. Recently,
calcium dysregulation in astroglial networks has been described in mu-
tant mouse models, providing further insight into disease pathogenesis
[13]. Mitochondrial, axon and dendrite membrane dynamics may be
aberrantly affected by disrupted iPLA2β. Axonal spheroids, the histo-
pathological hallmark of PLA2G6-associated disease, represent the de-
generation of mitochondrial inner membranes [20,21,22]. Whether
this disruption of mitochondrial architecture affects respiratory chain
function is unknown, asmitochondrial investigations are not commonly
undertaken in PLAN. The insidious onset of disease in Patient 5warrant-
ed detailed neurometabolic investigation, including muscle biopsy
which was undertaken at 11 years. Muscle respiratory chain enzyme
analysis revealed severely reduced cytochrome oxidase (COX) activity.
Of the respiratory chain enzymes, cytochrome oxidase is particularly
vulnerable to oxidative stress [22] and calcium dysregulation in mito-
chondria and astrocytes results in oxidative damage in the mouse
model [13]. Normally functioning VIA-iPLA2 protects mitochondria
from oxidative stress and valid mitochondria are necessary to meet
the high energy demands of neuronal function. Degeneration of mito-
chondrial inner membranes has been observed in the PLA2G6 knock-
out mouse [19]. It is possible therefore that the low COX activitymeasured in Case 5 may be secondary to oxidative stress due to im-
pairedVIA-iPLA2, since secondary derangement of respiratory chain en-
zymes is not reported in neurogenic muscle. There is one other atypical
PLAN case reported in the literature in whom respiratory chain com-
plexes were measured, demonstrating global deﬁciency of all com-
plexes on muscle biopsy at 12 years of age, in the presence of reduced
mitochondrial density [23]. Mitochondrial degeneration releases
stress-inducers including reactive oxygen species, cytochrome c and
lipid peroxisomes, resulting in cumulative mitochondrial degeneration
with the absence of normally protective VIA-iPLA2 contributing to fur-
ther damage [19]. We postulate that such secondary respiratory chain
enzyme deﬁciencies in PLAN may progress over time, and the impact
of oxidative damage to the mitochondria secondary to calcium dysreg-
ulation may be cumulative, paralleling clinical decline. Indeed, the im-
pact of PLA2G6mutations on the mitochondrion and respiratory chain
requires further evaluation, and whether anti-oxidant therapy may
have a protective role in preventing secondary respiratory chain dys-
function [2, 24].
PLAN is relentless and irreversible, and currently no diseasemodify-
ing treatments exist. For infantile onset PLAN, disease course is themost
progressive with rapidly ensuing spasticity, contractures, cognitive de-
cline in childhood, and death often reported at the end of the 1st decade.
Atypical NAD seems to have a less severe disease course, and the rarity
of adult onset PLAN precludes prognostication, although some adults
with this form of disease do show rapid cognitive decline from disease
onset in early adulthood. As our case series highlights, treatment strat-
egies focus on a multidisciplinary approach to optimise nutrition,
prevent cardiorespiratory complications and maintain orthopaedic vig-
ilance [1]. Pharmacological agents are often used to manage symptoms
such as gastro-oesophageal reﬂux (anti-reﬂux agents), excess secretions
(glycopyrrolate, hyoscine) and dystonia/spasticity (trihexyphenidyl/
baclofen) [1]. As we have discussed, contracture management can be
challenging, requiring not only orthotics but also more invasive strate-
gies such as botulinum toxin and tendon lengthening. As the TIRCON
(Treat Iron Related Childhood Onset Neurodegeneration FP7 277984-
2) trial evaluates the potential efﬁcacy of the iron chelator, deferiprone
in PKAN patients, there is optimism for its extrapolation to other NBIA
disorders, including PLAN, should it be beneﬁcial. Further unravelling
of the function of PLA2G6 and interacting pathways will be fundamental
to development ofmore rational and speciﬁcmolecular-based therapeu-
tic strategies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgme.2014.03.008.
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